JPRN-UMIN000037395
Completed
未知
Prospective Cohort Study of Endocrine Therapy with Abemaciclib for Chemotherapy-Treated Metastatic Breast Cancer - Abemaciclib cohort study
CSPOR-BC0 sites180 target enrollmentNovember 1, 2019
ConditionsBreast cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Breast cancer
- Sponsor
- CSPOR-BC
- Enrollment
- 180
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
nder analyzing
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Exclusion Criteria 1\)Women for whom endocrine therapy is not indicated. 2\)Women who require oxygen inhalation because of dyspnea under resting conditions. 3\)Women who have previous history of gastrectomy or small bowel resection, except for mucosal resection. 4\)Women who have Crohns disease, ulcerative colitis, or chronic diarrhea of Grade 2 or higher. 5\)Women who are pregnant or nursing. 6\)Women undergoing treatment for bacterial or fungal infection. 7\)Women who have active hepatitis B or C. 8\)Women who have serious cardiac disease. 9\)Women whose primary care physicians considered that they are unsuitable for inclusion in this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast CancerBreast CancerEstrogen Receptor-positive Breast CancerHealthyNCT03719495Duke University68
Unknown
Not Applicable
Prospective Observational Study of Antitumor Activity Correlation Between Hormonal Therapy and Expression miRNA100Breast CancerNCT02950207Fondazione del Piemonte per l'Oncologia180
Unknown
Not Applicable
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the BreastBreast CancerNCT04666805First Hospital of China Medical University1,354
Completed
Phase 2
Preoperative Window of Endocrine Therapy Provides Information to Increase ComplianceNewly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast CancerNCT01614210University of Utah52
Terminated
Not Applicable
EndoPredict® Extended Endocrine Trial (EXET)Primary Invasive Breast CancerNCT04016935Myriad Genetic Laboratories, Inc.855